358 related articles for article (PubMed ID: 16428483)
1. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer biomarkers in urine.
Chambers AF; Vanderhyden BC
Clin Cancer Res; 2006 Jan; 12(2):323-7. PubMed ID: 16428467
[No Abstract] [Full Text] [Related]
3. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
[TBL] [Abstract][Full Text] [Related]
6. Classifications of ovarian cancer tissues by proteomic patterns.
Zhu Y; Wu R; Sangha N; Yoo C; Cho KR; Shedden KA; Katabuchi H; Lubman DM
Proteomics; 2006 Nov; 6(21):5846-56. PubMed ID: 17068758
[TBL] [Abstract][Full Text] [Related]
7. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
8. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
Morita A; Miyagi E; Yasumitsu H; Kawasaki H; Hirano H; Hirahara F
Proteomics; 2006 Nov; 6(21):5880-90. PubMed ID: 17022098
[TBL] [Abstract][Full Text] [Related]
9. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
12. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
13. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins.
Li B; An HJ; Kirmiz C; Lebrilla CB; Lam KS; Miyamoto S
J Proteome Res; 2008 Sep; 7(9):3776-88. PubMed ID: 18642944
[TBL] [Abstract][Full Text] [Related]
14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
17. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
18. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
19. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
[TBL] [Abstract][Full Text] [Related]
20. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
